DXVX Launches 12 Microbiome-Based Products in Global Market

DXVX is advancing its position as a specialized microbiome company by launching 12 types of beneficial bacteria products based on the microbiome in the global market.

DXVX announced on the 25th that it plans to release 12 types of microbiome-based proprietary brand products jointly developed with Italy's AAT Institute of the Kori Group, targeting a launch in the second half of the year. These products are developed and manufactured locally in Italy and will be simultaneously launched in Europe, Korea, China, and the United States.

The microbiome-based products to be released this time are designed for everyday health management, including immune enhancement, cold supplements, gut health, digestive function improvement, anti-aging, detoxification, skin troubles, and vision. They target all age groups across the life cycle, including infants, women, middle-aged, and seniors.

Kori Italy, after two years of research with the AAT Institute, is preparing for an August launch. In particular, by applying the AAT Institute's Synteractive Formula European patented technology, the synergy effect between raw materials has been maximized, and the stability of beneficial bacteria has been significantly improved.

The Italian AAT Institute is a microbiome-specialized research institute spun off from the Catholic University of Rome, led by European microbiome expert Dr. Lorenzo Morelli. The products to be launched are known to be part of the various pipelines of microbiome-based pharmaceuticals and health functional foods owned by the AAT Institute that have been commercialized.

A DXVX official stated, “These are functional products effectively blended with natural substances that have recently gained attention. Targeting the global market, they have obtained European food safety certification and will be officially launched in Europe, as well as in Korea, China, and the United States.” He added, “In addition to the 12 products imported from Italy, we plan to release additional microbiome-based functional products domestically.”

Meanwhile, DXVX is reported to be planning to launch various bio-healthcare products globally, including microbiome-based new drugs and health functional foods through diagnostics, following its recent full-scale entry into the Chinese pharmaceutical market starting with antibiotics.

This content was produced with the assistance of AI translation services.